Candidate integrin inhibitors for ovarian cancer treatment.
| Drug name||Type||Target||Preclinical data in gynecologic cancer||Manufacturer||Ref.|
|Volociximab (M200)||Chimeric antibody||α5β1||i.p. treatment reduced tumor burden and ascites in SKOV-3ip1 ovarian cancer mouse xenografts by 83% and 97%, respectively.||Protein Design Labs|||
|ATN-161||Peptide||α5β1||i.v. (1 mg/kg) injection inhibited the outgrowth of metastases at lung, liver, or spleen in a metastasis model mouse of MDA-MB-231 breast cancer cell lines.||Attenuon LLC|||
|Etaracizumab (MEDI-522)||Humanized antibody||αvβ3||i.p. treatment decreased tumor burden in the SKOV3ip1 and the HeyA8 mouse models by 36 and 49%, respectively and reduced the number of proliferating cells but not microvessel density.||Medimmune|| |
|Intetumumab (CNTO95)||Human antibody||αvβ3 αvβ5||Low doses (0.15–1.25 μg/mL) of intetumumab were effective in inhibiting adhesion and migration of 6 uterine serous papillary carcinoma cell lines in vitro. ||Centocor|||
|Cilengitide (EMD-121974)||Peptide||αvβ3 αvβ5||αvβ3-integrin overexpression on SKOV3ip1 cells impaired invasion, protease expression, and colony formation in vitro. Cilengitide may have detrimental effects against ovarian cancer.||Merck KGaA|||